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Mitochondrial DNA mutations are an important cause of neurological disease. The clinical presentation is
very varied in terms of age of onset and different neurological signs and symptoms. The clinical course varies
considerably but in many patients there is a progressive decline, and in some evidence of marked
neurodegeneration. Our understanding of the mechanisms involved is limited due in part to limited
availability of animal models of disease. However, studies on human post-mortem brains, combined with
clinical and radiological studies, are giving important insights into specific neuronal involvement.
© 2009 Elsevier B.V. All rights reserved.
1. Introduction
Mitochondrial DNA (mtDNA)mutations are increasingly becoming
recognised as important causes of disease. Theywere first identified in
1988 [1,2] andwere initially thought to be relatively rare, however, the
incidence of known pathogenic mutations in the general population
has recently been investigated. These studies have shown that
approximately 1 in 500 individuals carry the m.3243ANG mutation
[3], which can cause severe neurological disease, with a similar figure
observed for the m.1555ANG mutation, which causes aminoglycoside-
induced deafness [4,5]. Another approach to study the incidence of
mtDNA disease is to document the number of clinically affected cases
within a specific geographic region. This approach is limited because
there is marked clinical variability which means many patients go
unrecognised and because patients may not be referred to specialist
centres. However, even these studies show there is a high disease
burdenwith at least 1 in 10,000 of the adult population suffering from
mtDNA disease [6].
In the twenty years since mtDNA mutations were first associated
with human disease it has become apparent that the central nervous
system is one of the predominant systems affected, especially in those
patients with a severe phenotype. Despite this we only have limited
understanding of themechanisms of neurodegeneration. One thing that
has become clear, however, is that certain mtDNA mutations have
predilections for causingneurodegeneration in certain areas of the brain.
Patients with mtDNA disease present with a plethora of neurolo-
gical manifestations, in particular, optic atrophy, ataxia, seizures,
progressive weakness, dementia, stroke-like episodes and extrapyr-
amidal features. The unique nature of mitochondrial genetics means
that patients with the same mutation may have very different clinical
presentations. This highlights the complexity of clinical phenotyping,
and the importance of understanding the underlying pathogenesis
and developing treatments for patients with mtDNA disease.
In addition to the increasing number of patients being recognised
with mtDNA disease, mtDNA mutations have also been found to be
present in high levels in several ageing tissues. For example, mtDNA
mutations have been identified in the neurons of the substantia nigra
in both elderly control subjects and in patients with Parkinson's
disease [7,8]. There is a direct link between the presence of these
mutations and a mitochondrial defect in these cells. Thus a greater
understanding of diseasemechanisms in patients withmtDNA disease
may also give important insights into neuronal loss or dysfunction in
ageing and age-related neurodegenerative diseases [9–11].
This review focuses entirely on the neurological and neuropatho-
logical features of patientswithmtDNA disease.Mitochondrial disease
can also be caused by nuclear gene disorders [12], many of which
mimic the features seen in mtDNA disease, but these are not discussed
here. We first review important aspects of mitochondrial genetics,
crucial if we are to understand the pathogenesis of the changes seen.
We then describe the clinical features seen in patients and the
associated neuropathology. Unfortunately at present there is limited
treatment available for patients with mtDNA mutations and we
discuss various potential therapies.
2. Mitochondria — structure and function
Mitochondria are double-membrane subcellular organelles which
were originally primitive, autonomous, bacteria-like organisms. Dur-
ing evolution these organisms were engulfed by larger eukaryotic
cells; enjoying protection in return for providing energy. The relation-
shipwas so successful thatwe are nowdependent onmitochondria for
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over 90% of our cellular energy in the form of ATP generated by the
process of oxidative phosphorylation. This endosymbiotic relationship
is almost certainly the origin of the mitochondrial genome which
rather surprisingly has been maintained throughout evolution [13].
Mitochondrial function is closely linked to its unique double-
membrane structure. The outer mitochondrial membrane is porous to
small molecular weight substances and encapsulates the mitochondria.
The enzymes of the mitochondrial respiratory chain are found within
the highly folded innermembranewhich separates thematrix from the
intermembrane space. The matrix contains the mitochondrial genome,
as well as the enzymes involved in the tricarboxylic acid cycle and
mitochondrial fattyacid oxidation. The cristae, orfinger-like projections,
of the innermitochondrialmembraneensure themaximumsurfacearea
between the biochemical substrates in the matrix and the respiratory
chain enzymes. The inner membrane is also highly impermeable
allowing the free passage of only water, oxygen and carbon dioxide.
The primary function of mitochondria is the generation of ATP
from ADP by the process of oxidative phosphorylation. This process is
dependent upon fivemultisubunit complexes (I–V), only one of which
(complex II) is totally encoded by the nuclear genome. All the other
complexes have subunits encoded by both mitochondrial and nuclear
genomes, making them vulnerable to mutations of either genome.
Through a succession of oxidoreduction reactions, electrons are
transported along the respiratory chain to molecular oxygen. This
generates an electrochemical gradient by the extrusion of protons.
This gradient then drives ATP synthesis by complex V (ATP synthase).
Mitochondria are often considered as discrete organelles however
this is not the case with mitochondria often forming networks within
cells. There is constant fission and fusion of mitochondria and if this
process is disrupted then mitochondrial disease develops and
interestingly accumulation of mutations [14]. The fission and fusion
process is also thought to be important in targeting mitochondria for
turnover by the process of autophagy [15].
3. Mitochondrial genetics and biology
3.1. The mitochondrial genome
Mitochondrial DNAwas identified in 1963. It has subsequently been
shown that multiple copies of this double-stranded, super-coiled,
circular molecule are found within the matrix of mitochondria. There
are between 2 and 10 mtDNA copies per mitochondrion, resulting in
1000–100,000 copies per cell. This is the only extra chromosomal DNA
in human cells. The mitochondrial genome consists of 16,569 base
pairs and the entire mtDNA sequence was first reported in 1981 [16]
and is referred to as the Cambridge reference sequence. This has since
been revised to eliminate errors caused by the use of bovine fragments
in the original sequencing project [17].
The mitochondrial genome encodes 13 essential respiratory chain
subunits as well as the genetic information for the coding of 2 ribosomal
RNAs (rRNA) and 22 transfer RNAs (tRNA) required for the intramito-
chondrial sequence of these proteins. The majority of mitochondrial
proteinsarenuclearencodedand theseproteins formtheother subunitsof
the respiratorychain aswell those required formtDNAmaintenance. Thus
nuclear gene mutations of the proteins involved in mtDNA replication
and/or repair will have profound effects on the mitochondrial genome.
The mitochondrial genome seems to be particularly vulnerable to
damage. It has been proposed that the mutation rate is at least 10
times greater than that of the nuclear genome and there are a number
of possible reasons for this. The mtDNA lacks protective histones and
has limited repair mechanisms. It is also susceptible to nucleolytic
attack from the free radicals produced by oxidative phosphorylation.
Combined with this the mtDNA consists entirely of exons and
consequently there is very little redundancy. As a result a point
mutation or deletion can very quickly lead to a biochemical defect.
3.2. MtDNA replication, transcription and translation
The two strands of the mitochondrial genome differ in their
distribution of bases C and G making one strand denser (called the
heavy or H strand) than the other (light or L strand). There is a non-
coding control region of about 1.1 kb which is often referred to as the
D-loop. This region contains essential sequences for initiation of
replication and transcription.
3.2.1. MtDNA replication
Individual mtDNA can replicate independently of the cell cycle and
is therefore described as relaxed. Clayton originally described mtDNA
replication as an asynchronous mechanism originating from two
points OH and OL [18]. An RNA primer generated from the light chain
initiates replication of an mtDNA molecule at the origin of the heavy
chain, OH, found in the D-loop. DNA polymerase gamma, encoded by a
nuclear gene, then synthesises the DNA strand. The origin for the light
chain, OL, is a small non-coding region surrounded by tRNA genes. It is
exposed when the heavy strand passes this region, about 2/3 of its
way around the genome and L-strand replication is initiated in the
opposite direction.
Recently a strand-coupled method has been proposed inwhich the
two strands are synthesised simultaneously [19]. In this model of
mtDNA replication, lagging L-strand synthesis starts shortly after the
initiation of replication at OH and may involve extensive RNA
synthesis prior to DNA synthesis. However, there remains debate as
to which form of mtDNA replication predominates and even whether
different forms of replication occur in different tissues.
3.2.2. MtDNA transcription
There is less contention as regards mtDNA transcription and many
of the proteins involved have been identified and an in vitro system
established. Mitochondrial transcription is initiated from promoters
on both H and L-strand generating polycistronic transcripts, which are
then processed to produce the individual mRNA, rRNA and tRNA
molecules. This process requires a mitochondrial RNA polymerase, a
transcription activator called TFAM, and either mitochondrial tran-
scription factor B1 or B2 [20].
3.2.3. MtDNA translation
Mitochondrial translation is still an area in which there are many
uncertainties. It is a process controlled by nuclear encoded proteins
[21] which include two specific mitochondrial initiation factors [22],
three mitochondrial elongation factors [23] and at least one termina-
tion release factor [24].
3.3. Mitochondrial DNA mutations
The first pathogenic mtDNAmutations were described in 1988 and
since then over 300 mtDNAmutations have been reported (Mitomap)
[25]. These mutations take the form of either point mutations or
rearrangements (deletions or duplications). They result in a biochem-
ical defect either by affecting protein synthesis if the sequence of a
tRNA or rRNA is disrupted; or, the normal functioning of the
respiratory chain if one of the genes encoding the subunit is affected.
There are several important features unique to the mitochondrial
genome when we consider its role in human disease.
3.3.1. Homoplasmy and heteroplasmy
There are multiple copies of the mitochondrial genome in all cells.
The normal situation is that all the copies of mtDNAwithin the cell are
identical and have wild-type mtDNA sequence. In the presence of an
mtDNA mutation all copies of the mitochondrial genome may be
affected which is known as a homoplasmicmutation. Most pathogenic
mutations only affect a proportion of the mitochondrial genomes and
this is called heteroplasmy.
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3.3.2. Threshold effect
In the presence of a heteroplasmic mtDNA defect not all cells show
evidence of a biochemical defect, observed as a mosaic of cells lacking
mitochondrial enzyme activity, often as cytochrome c oxidase
deficiency [26]. This is due to a threshold effect with mitochondrial
function only being affected if there are high levels of mutatedmtDNA
within individual cells [27]. It is thought that the critical factor is the
amount of wild-type mtDNA present to complement the defective
mtDNA. Typically between 70 and 90%mutated mtDNA is required for
the clinical phenotype to develop [28], but this varies markedly for
different mtDNA mutations. The threshold level also appears to vary
for different cell types and this may explain why some tissues are
more affected in the presence of some mtDNA mutations than others.
3.3.3. Mitotic segregation
In dividing cells not all daughter cells will contain the same level of
mutated mtDNA. In cells undergoing mitotic division the cells with
high levels of mtDNAmutation appear to be at a disadvantage and the
mtDNA mutation is lost during life [29]. In post-mitotic cells such as
muscle and neurons there cannot be loss of the mutated mtDNA by
mitotic segregation and this may be a factor in their frequent
involvement in mitochondrial disease.
3.3.4. Maternal transmission and bottleneck
Numerous population based genetic studies have shown that the
transmission of mtDNA is purely maternal. Indeed the uniparental
inheritance of mtDNA, as well as the high rate of mutation, has made
mtDNA invaluable in charting the evolution of man [30]. Maternal
inheritance is also very important in the context of mitochondrial
diseases. Large maternal pedigrees have been identified, although
sometimes there are apparently unaffected family members. This may
be due to variation in the expression of the disease or in the presence of
low levels of heteroplasmic mutations. Heteroplasmic mutations can
vary widely between offspring due to the presence of a mitochondrial
bottleneck during development. The copy number of mtDNA molecules
in primordial germ cells falls to very low levels [31–33]. This bottleneck
has a crucial role in preventing the transmission of very deleterious
mutations. This purifying selection seems to occur during the cell
replicationphase inprimordial germcells. The stage in theprocesswhich
differences in heteroplasmybetween offspring occur is less certain, but it
is a major feature in many families with heteroplasmic mtDNA disease.
4. Possible mechanisms of neurodegeneration in mtDNA disease
Despite research to elucidate the specific pathological mechanisms
leading to cell loss inmtDNAdisease ourunderstanding remains limited.
Compromised respiratory function as a consequence of impaired ATP
synthesis remains the unifying biochemical defect; however the
question of how different mutations, particularly those that affect the
same enzyme complex, can lead to very different phenotypic presenta-
tions remains largely unexplained. It has been proposed that specialised
processes within each cell, particularly within neuronal tissue, have a
different energy requirement for example, for neurotransmitter release,
ion pumping and electrical transmission [34]. In a similar way to tissue-
specific dysfunction, cells may be functionally affected in differentways.
Evidence is accumulating for a role of apoptosis-induced cell loss,
production of reactive oxygen species and altered calciummetabolism
leading to neuronal dysfunction and neuronal degeneration although
the relative importance of these three factors remains ambiguous. By
identifying the underlying pathogenesis it may be possible to identify
therapeutic solutions.
4.1. Oxidative stress
Oxidative damage has been implicated as a precursor to apoptosis
or programmed cell death. Reactive oxygen species (ROS) are
predominantly formed as a by-product of oxidative phosphorylation
in the mitochondria [35] with at least 9 submitochondrial ROS-
producing sites identified. It is estimated that a significant proportion
of oxygen is converted to the superoxide anion during oxidative
phosphorylation which is subsequently converted to hydrogen
peroxide [36], an importantmediator of cellular damage. The enzymes
of the respiratory chain are in close proximity to the mtDNAwhich, in
combination with the lack of protective histones, predisposes the
genome to mutagenesis. These findings are consistent with studies
into pathological mechanisms in specific mtDNA diseases whereby
increased ROS production is seen in neuronal NT2 cybrid cells with the
LHONmutation. In addition, exogenous administration of antioxidants
can protect against ROS-mediated damage in cybrid cells containing
the m.8993TNG NARP mutation [37].
There are unfortunately very few models of mtDNA disease in
which to explore mechanisms [38]. This is because mtDNA mutations
have limited capacity to pass through the germ-line. An alternative
approach has been to develop transgenic mice with mutation in the
proof reading domain of the mitochondrial polymerase gamma
[39,40]. These mice accumulate mtDNA defects and interestingly
there was no evidence of increased sensitivity to oxidative stress-
induced cell death or of increased levels of ROS ([40,41].
4.2. Apoptosis
An increase in the level of ROS or removal of endogenous
antioxidants could precipitate apoptosis within a cell. Virtually every
cell contains the biochemical participants required to undergo pro-
grammedcell death andmuchresearchhas recently been focusedon the
extracellular and intracellular pathways that initiate apoptosis. A
specific mitochondria-induced pathway has been proposed although
mitochondria may be involved in several different pathways. There is
some evidence of apoptosis in muscle biopsy samples and cell cultures
from patients with specific mtDNAmutations and on autopsy examina-
tion neurons are characterised by the shrunken nuclei of apoptosis.
A number of characteristics have focused attention on mitochon-
dria during apoptosis: the early changes of loss of membrane
potential, increased porosity of the mitochondrial membrane and
the release of proteins from the intermembranous space into the
cytosol [42]. One of the key regulators of apoptosis has been identified
as the Bcl-2 family of proteins which are located on the mitochondrial
membrane. These proteins operate the bulk of control over the release
of pro-apoptotic proteins including cytochrome c and apoptosis-
inducing factor, following which, an apoptosome is formed and the
capase cascade is initiated leading terminally to apoptosis [43].
Mitochondria normally co-operate with the endoplasmic reticu-
lum (ER) to ensure homeostasis within the cell. The ER ensures the
normal folding of proteins and is a large source of stored calcium ions
within the cell which are heavily involved in the transduction of
electrical stimulation to molecular response within neurons and have
been implicated in the pathways to cell death. The effects of different
mitochondrial mutations on mitochondrial and ER initiated apoptotic
pathways vary. In some cases themutations actually appear protective
of cell loss [44].
Dysfunction of calcium homeostasis appears to contribute inde-
pendently to neurodegeneration. Mitochondria have been shown to
have an established role in calcium buffering with the capacity to
absorb a large amount of calcium rapidly from the cytosol, driven by
the large electrochemical gradient across the inner mitochondrial
membrane. The calcium is released slowly back into the extracellular
space through recycling via the Ca2+-ATPase. In mtDNA disease
dysfunction may occur due to a decrease in the electrochemical
gradient or impairment of the ATP-ases involved in recycling.
Increased basal calcium levels and sustained elevation following
electrical stimulation have been observed in fibroblasts of patients
with the m.3243ANG MELAS mutation.
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5. Neurological and neurodegenerative features associated with
mtDNA mutations (Table 1)
5.1. MtDNA point mutations
5.1.1. m.3243ANG — mitochondrial encephalopathy, lactic acidosis and
stroke-like episodes (MELAS)
5.1.1.1. Clinical features. The most common presentation of MELAS is
a stroke-like episode which often occurs before the age of twenty.
Patients typically present on a background of normal psychomotor
development, although there may be evidence of short stature. The
stroke-like episodes may develop over hours or days and are
frequently associated with a severe, migraine-like headache as a
prodrome. Seizures are frequently associated andmay be present early
in the course of the disease, raising the possibility that they could be
involved in the pathogenesis. The clinical features of each episode vary
according to the location of the lesion and include hemiparesis, focal
seizure and cortical visual field loss.
Cortical lesions are observed radiologically and often do not fit
with a vascular territory. Diffusion MRI studies have reported a high/
normal diffusion coefficient in the presence of MELAS stroke-like
episodes compared to the decrease observed in ischaemic lesions.
However, a more recent study of serial diffusion MRI scans in one
MELAS patient has shown initial restricted diffusion in the context of
the acute phase [45]. A restricted diffusion pattern should therefore
not exclude MELAS. The radiological lesions may resolve rapidly in
keeping with the clinical picture. The pathogenesis of these stroke-
like episodes remains controversial.
Intermittent periods of encephalopathy characterised by raised
CSF and plasma lactate but not associated with seizures or stroke-like
episodes are also seen in patients with m.3243ANG MELAS. A
combination of recurrent encephalopathy and stroke-like episodes is
thought to cause a slowly progressive neurodegeneration leading in
some patients to cognitive decline and dementia [46].
5.1.1.2. MtDNA mutation. The majority of patients (N80%) with
MELAS have them.3243ANGmtDNA pointmutation. Patients with this
mutation vary from asymptomatic carriers to severely affected
individuals with the MELAS syndrome [47]. Patients with the
m.3243ANG may also develop diabetes, deafness, ophthalmoplegia
(see below), myopathy, gut immobility and cardiac abnormalities
stressing the range of different phenotypes seen in patients with
mtDNA disease. The m.3243ANG mutation is located in the MTTL1
gene [48], however, other mutations in this tRNA gene, other tRNA
genes and protein encoding genes may also cause the MELAS
syndrome [49].
5.1.1.3. Neuropathological studies. Neuropathological studies have
identified infarct-like areas in the white matter of the cortex and
subcortex, concentrating principally in the parietal, temporal and
occipital lobes [50]. The cerebellum, thalamus and basal ganglia may
also be affected [51,52] (Fig. 1). Infarcts are multiple, asymmetrical
and, unlike vascular lesions, are not restricted to a particular vascular
territory. Microscopically, however, they are similar to true infarcts in
both acute and chronic stages. They may be associated with
considerable neuron loss, astrogliosis and microvauolation [53].
Ventricular dilatation accompanying cortical atrophy due to extensive
neuronal loss is also seen as MELAS progresses.
Calcification of the vasculature of the basal ganglia is also a
common neuropathological feature seen in patients with MELAS
symdrome and can be identified on neuroimaging [51,54]. Despite this
finding the neurones in the basal ganglia are relatively spared and
patients rarely present with evidence of basal ganglia dysfunction. The
pattern of calcification is similar to that seen in normal ageing and it is
possible that the process is simply accelerated by the mitochondrial
dysfunction in MELAS.
Extensive damage to the cerebellum is also common in MELAS
with loss of Purkinje cells and development of cerebellar ataxia
clinically. In severely affected patients cactus formation is visible on
Purkinje cells which are thought to be due to the accumulation of
abnormal mitochondria within dendrites similar to that seen in
ragged red fibres on muscle biopsy.
5.1.1.4. Mechanisms. One theory for the generation of the necrotic
lesions in MELAS is the vascular hypothesis which proposes that a
deficit in oxidative phosphorylation in cerebral arteries causes an
angiopathy which leads to alterations in vascular tone, ischaemia and
infarction. This is suggested by the presence of enlarged, abnormal
mitochondria in the endothelial and smooth muscle cells of these
arteries [55]. Other studies suggest that the proliferation of mitochon-
dria may be a consequence rather than a cause of cerebral ischaemia.
Compelling evidence for the vascular hypothesis in MELAS comes
from the post-mortem examination of the blood vessels of two
patients with MELAS. There was widespread respiratory chain
deficiency in the blood vessels and high levels of the m.3243ANG
Table 1
Genetics Clinical features Neuropathology
MELAS (mitochondrial encephalopathy,
lactic acidosis, and stroke-like
episodes)
mtDNA encoded tRNA and ND
gene protein encoding mutations
(N80% A3243G in MTTL1 gene)
Stroke-like episodes, lactic acidosis,
encephalopathy, myopathy
Cardiomyopathy, deafness, diabetes
Multiple, asymmetrical infarcts not restricted to
a vascular territory (mainly parietal, temporal,
occipital lobes)
Basal ganglia calcification and cerebellar
involvement
MERRF (myoclonic epilepsy and ragged
red fibres)
Commonly mtDNA encoded
tRNALys mutation (m.8344ANG)
Myoclonic epilepsy, cerebellar ataxia,
pyramidal signs and hearing loss, optic
atrophy
Neuron loss especially dentate nucleus in
cerebellum. Less severe involvement of gracile
and cuneate nuclei, Clarke's column, inferior
medullary olives, red nucleusCardiac conduction abnormalities, lipoma
LHON (Leber's hereditary optic
neuropathy)
m.11778GNA (MTND4) Optic neuropathy, dystonia Retinal ganglion cells loss with gliosis
m.3460GNA (MTND1) Cardiac conduction defects
m.14484TNC (MTND6)
NARP (neuropathy, ataxia and retinitis
pigmentosa)
m.8993TNG and TNC Peripheral neuropathy, ataxia, retinitis
pigmentosa, seizures and dementia
Leigh syndrome: Spongy changes, capillary
proliferation and condensation, tissue
rarefaction with spared intact neurones.
Symmetrical and necrotic lesions involving
especially basal ganglia and brainstem
Leigh syndrome Leigh syndrome (developmental delay and
regression, respiratory failure (if mutation
load highN90%))
Single mtDNA deletions Large-scale single mtDNA deletion CPEO KSS
CPEO (chronic progressive external
ophthalmoplegia
4977 bp common deletion (1/3 of
patients)
CPEO, retinitis pigmentosa, cerebellar ataxia,
cognitive impairment, deafness, dysphagia,
cardiomyopathy, cardiac conduction defects,
short stature, endocrinopathies
White and grey matter spongiform degeneration
involving cerebellum, cerebrum and brainstem
(sparing of cortex and dentate nucleus)KSS (Kearns–Sayre Syndrome)
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mutation [53]. These results were compared to similar regions from
controls which were found to have normal respiratory chain function.
The presence of respiratory deficient blood vessels throughout the
brain, however, implies that another mechanism must be responsible
for dictating the cortical selectivity of brain lesions.
Electron-microscopy has demonstrated abnormal mitochondria
within neurones as well as the brain vasculature [56] and data from
MR spectroscopic data has shown impaired oxidative metabolism and
increased concentrations of lactate in cortical lesions during acute
episodes. Observations of impaired glucose uptake in the occipital and
temporal regions with positron-emission tomography (PET) in a
patient with MELAS may correspond to a higher metabolic rate of
neurons in this region [57]. These findings have led to the formulation
of the metabolic hypothesis of neurodegeneration in MELAS, which
goes someway to explaining the focus of cortical lesion in the parieto-
occipital lobes where it is argued there may be a higher metabolic
demand on neurones.
5.1.2. 8344 ANG — myoclonic epilepsy and ragged red fibres
5.1.2.1. Clinical features. MERRF is a severe neurodegenerative
disorder, which often presents in childhood or early adulthood
following normal development [47]. The characteristic myoclonus is
often the presenting symptom. This progresses into a mixed picture of
myopathy, oftenwith pronounced proximal muscle wasting in a limb-
girdle distribution; and central neurological features of focal and
generalised epilepsy, cerebellar ataxia, optic atrophy, pyramidal signs
and hearing loss. A sensory ataxia may also develop from a loss of
proprioception due to peripheral sensorimotor neuropathy. The
combination of sensory and cerebellar ataxia with myopathy means
patients becomes progressively disabled over a period of several
decades. Non-neurological manifestations include re-entrant atrio-
ventricular tachycardias such as Wolff–Parkinson–White syndrome
and multiple lipomas especially in the cervical region. Dysrhythmias
can significantly reduce life expectancy with numerous examples of
sudden death under the age of 60 in families with a pedigree of
MERRF.
5.1.2.2. MtDNA mutation. MERRF is caused most commonly by a
point mutation in the MT-TK gene at position 8344 in the
mitochondrial genome [58]. MT-TK encodes the tRNALys which is
essential for protein synthesis.
5.1.2.3. Neuropathological features. The dentate nucleus is particu-
larly targeted in patients with the m.8433ANG mutation leading to
severe neuronal loss accompanied by astrocytosis. Some studies have
also demonstrated abnormally large mitochondria with inclusion
bodies in this area [59]. An interesting micro-dissection study of a
patient with m.8433ANG examined the proportion of mutant mtDNA
in different cell types. This identified the vulnerability to this mutation
of neurones in the dentate nucleus (Fig. 2) where 45% neuronal loss
was noted compared with 7% of cerebellar Purkinje cells. This loss
occurred despite the finding that the mutation load in Purkinje cells
was 97.6±0.7% compared to 89.0±1.5% in the dentate neurones [60].
Purkinje cell loss is usually mild in MERRF.
The gracile and cuneate nucleus, Clarke's column of the spinal cord,
the inferior medullary olives, the pons, and red nuclei of midbrain
have all been noted to suffer from some neuronal loss [51]. Although
infarct-like areas are found in MERRF as in MELAS, loss of cerebral
neurones is rare.
5.1.2.4. Mechanisms. The molecular genetics of the m.8433ANG
mutation have been explored in vitro with studies of cultured
myotubes containing the mutation [61]. In cells containing over 85%
mutant impaired protein translation was demonstrated, especially in
those proteins with a large number of lysine residues. The authors
postulate that the mutation was functionally recessive as a return to
15% wild-type restored translation and respiratory chain activity to
near normal activity. Further experiments with rho0 cell lines (native
mtDNA repopulated with mtDNA containing a specific mutation, in
this case the m.8344ANG mutation) have shown that with high levels
of mutant load there is a decrease in protein synthesis, oxygen
consumption and cytochrome c oxidase deficiency.
Muscle biopsy in MERRF shows evidence of mitochondrial
accumulations in the sub-sarcolemmal region which gives a char-
acteristic ‘Ragged Red Fibre” when a section of muscle is stained with
the Gomori trichrome. The name MERRF was devised before the
underlying genetic diagnosis was established and these changes are
not specific to patients with MERRF since evidence of mitochondrial
proliferation is common in many patients with mitochondrial disease.
Mitochondrial defects are now much better detected in muscle using
cytochrome c oxidase and succinate dehydrogenase histochemistry
[62].
5.1.3. m.11778GNA, m.3460GNA and m.14484TNC — Leber's hereditary
optic neuropathy
5.1.3.1. Clinical features. Leber's hereditary optic neuropathy (LHON)
is an organ-specific disease, targeting the optic nerve. Clinically this
presents with a subacute or acute, painless, central visual loss usually
between the ages of 20 and 40. Visual loss is typically unilateral with
the other eye usually becoming affected within the next two months.
Microangiopathy, disk pseudooedema, peripapillary teleangiectasia,
tortuous retinal vessels and visual loss ranging from no light
Fig.1.m.3243ANGMELASmutation: Infarct-like lesion in cerebellar cortex involving the
molecular layer, Purkinje cell layer, granular cell layer and white matter (A). There is
abnormal dendritic arborisation from remaining Purkinje cells, in vicinity of infarct-like
lesion. Swollen axonal terminal synapsing on Purkinje cells shown by arrow (B).
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perception to 20/60 can all be determined by clinical examination.
Whilst the majority of patients withm.11778ANGwho have symptoms
develop LHON, there have been a few reports of other neurodegen-
erative phenotypes including an MS like picture and early-onset
dystonia [63,64]. The patients with dystonia often do not have visual
problems highlighting once again the remarkable clinical variability
seen in these diseases. Cardiac conduction defects such as Wolff–
Parkinson–White syndrome are also seen in some patients.
5.1.3.2. MtDNA mutation. LHON has a key role in the history of
mitochondrial research. First described in 1871 by Thomas Leber as a
familial neuro-opthalmologic disease, LHONwas the first disease to be
recognised as being due to a point mutation in the mitochondrial
genome — m.11778GNA [2]. Two other mutations are now also
recognised as primary LHON mtDNA mutations m.3460GNA and
m.14484TNC. In total these three genes are present in at least 95% of
LHON cases [65].
5.1.3.3. Neuropathology. The primary disturbance in patients with
LHON is in the retinal ganglion cells and this is reflected in the
neuropathology [66]. There is dramatic loss of this layer in the retina
as well as the retinal nerve fibre layer, predominantly affecting the
central fibres. There is also evidence of on-going neurodegeneration in
numerous glial cells and the presence of macrophages filled with
lipofuscin.
5.1.3.4. Mechanism. The mutations at m.11778GNA, m.3460GNA and
m.14484TNC all involve complex I genes (located in genes MTND4,
MTND1 and MTND6 respectively). The progression of disease appears
to depend upon the responsible mutation with 71% of patients with
the m.14484TNC mutation showing some recovery, compared to 4% in
m.11778GNA [67].
Themechanisms proposed for the pathogenesis of thesemutations
are complex and likely to be multifactorial. The selective vulnerability
of the retinal ganglion cells may arise through a combination of
bioenergetic failure, oxidative stress, glutamate toxicity, abnormal
mitochondrial dynamics and axonal transport and an increased
susceptibility to apoptosis [66].
LHON is usually due to a homoplasmic mtDNAmutation; all copies
are mutated mtDNA. As such, all maternal offspring will inherit the
mutation, however, whilst 50% of males will be affected only 10% of
females will develop visual loss. This incomplete penetrance implies a
role for nuclear genetic and environmental factors in modulating the
expression of the mutation, whilst the male preponderance suggests
that there may be an X-linked susceptibility locus [68].
5.1.4. m.8993TNG and m.893TNC — neuropathy, ataxia, and retinitis
pigmentosa and Leigh Syndrome
5.1.4.1. Clinical features. Peripheral neuropathy is the principle
feature of this diseasewith other neurological complications including
ataxia, retinitis pigmentosa, developmental delay, seizures and
dementia. On examination of the patient the neuropathy manifests
itself as proximal and distal neurogenic limb weakness, absent ankle
jerks and loss of vibration sensation. It has subsequently been
recognised that patients with a mutant load greater than 90% have a
predominant CNS presentation which usually occurs in infancy [69].
This is known as Maternally Inherited Leigh Syndrome (MILS). As
Leigh Syndrome progresses it is associated with stepwise develop-
mental delay followed by developmental regression and death due to
respiratory failure. Many other mutations, both mitochondrial DNA
and nuclear, can cause Leigh's Syndrome suggesting the developing
brain is particularly vulnerable to disturbances of energy metabolism.
5.1.4.2. MtDNA mutation. The m.8993TNG mutation was first
described in a single family inwhich four members had a combination
of peripheral neuropathy, ataxia and retinitis pigmentosa [70].
Following this original report, it has also been recognised that a
mutation at the same base m.899TNC may also cause the NARP/MILS
phenotype. Other mutations of the ATPase 6 gene may also cause the
NARP phenotype [71].
5.1.4.3. Neuropathological studies. The neuropathological findings in
Leigh's Syndrome are symmetrical, necrotic lesions involving the
white and greymatter [72] Fig. 3). The basal ganglia and brainstem are
particularly affected and although the clinical picture may be very
varied patients often present with symptoms of dysfunction in these
areas with respiratory abnormalities, nystagmus, hypotonia and
Fig. 2. m.8344ANG MERRF mutation: Severe neuronal loss seen in dentate nucleus of
patient (A) when compared with age matched control (B). The remaining neurons are
often respiratory deficient as shown by blue staining using cytochrome c oxidase/
succinate dehydrogenase stain (C).
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ataxia. Macroscopic examination and neuroimaging demonstrates
cystic degeneration particularly in the substantia nigra, periaqueduc-
tal grey and putamen. Microscopic changes are more widespread
throughout the brain with relative sparing of the cortex and the
mammillary bodies. A progression of pathology can be demonstrated
with early changes including neuropil oedema and spongy change;
capillary proliferation and condensation within or bordering affected
white and grey matter, and, tissue rarefaction, which can be severe.
Eventually this leads to necrosis. Even in these severely affected areas
there is evidence of intact individual neurons which would be unusual
in infarcts associated with hypoxia.
5.1.4.4. Mechanisms. The m.8993TNG and m.8993TNC mutations are
located within the ATPase 6 gene of the mtDNA. Crucially these
mutations do not involve cytochrome c oxidase deficiency and as such
on muscle biopsy analysis the characteristic ragged red fibres of
mitochondrial disease are not present, although there may be
evidence of denervation. Studies in blood cells have shown that the
m.8993TNG and m.8993TNC mutations both lead to low energy
production and ROS overproduction. However, the relative contribu-
tion of the two pathogenic components was different; the m.8993TNG
change mainly induced an energy deficiency, whereas the 8993TNC
favoured an increased ROS production. These results possibly
Fig. 3. Leigh's syndrome: There is bilateral symmetrical necrosis of the globus pallidus, substantia nigra and periaquaeductal grey matter (A,C) corresponding to areas of increased
FLAIR signal three weeks prior to death (B, C inset). Midbrain section stained with Klüver Barrera (D) for myelin and nerve cells, and microglia/macrophage marker CD68 (E)
highlights the selectivity of the pathology. (F, G) Increasedmicrovessel density andmicrovascular proliferation are typical of the fully developed lesion (arrows). (H) Early lesions are
characterised by neuropil microvacuolation and vascular ectasia and congestion with preservation of neurons (locus coeruleus) (D, Kluver Barrera; E, F immunohistochemistry for
CD68; G, H haematoxylin and eosin; F ×200, G, H ×400).
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highlight different pathogenic mechanisms generated by the two
different mutations at position m.8993.
5.2. Single large-scale mtDNA deletions
5.2.1. Chronic progressive external ophthalmoplegia
5.2.1.1. Clinical features. One of the most common presentations of
mtDNA disease in adults is chronic progressive external ophthalmo-
plegia (CPEO). CPEO is characterised by a progressive paralysis of the
eye musculature leading to ophthalmoparesis and ptosis. Ptosis is
frequently the presenting symptom and may be asymmetrical;
however, patients usually progress to bilateral disease. In patients
with CPEO there may be other clinical features dependent on the
underlying genetic defect, however, myopathy and fatigue are
common in all patients.
5.2.1.2. MtDNA mutation. CPEO is typically caused by sporadic large-
scale single deletions or multiple mtDNA deletions [73], although in
some patients an mtDNA point mutation is detected. Progressive
opthalmoplegia also presents as a clinical feature in several other
distinct deletion syndromes. A recent meta-analysis attempted to
correlate the type of deletion with the phenotype of the patient. It
demonstrated that although there is some overlap, the percentage of
deletion and the location of the deletion within the genome shows
differences between CPEO, Kearns–Sayre Syndrome and Pearson
Syndrome (a severe syndrome presenting in infancy with side-
roblastic anaemia with pancytopenia and exocrine pancreatic failure)
[74].
5.2.1.3. Neuropathological studies. There have been few studies of
extraocular muscles in this condition, but skeletal muscle biopsy
typically reveals cytochrome c oxidase (COX) deficient fibres. Some of
these fibres demonstrate characteristic sub-sarcolemmal accumula-
tion of abnormal mitochondria, the classical ragged red fibre. Single
muscle fibre analysis has revealed levels of pathogenic mtDNA
deletions above a critical threshold level of N80% mutant load in
these COX deficient fibres.
5.2.1.4. Mechanisms. The extraocular muscles (EOM) have a wide
dynamic range making their structure, biochemistry and immunology
distinct from skeletal muscle. This has been suggested as a reason for
their selective involvement in certain mitochondrial disorders [75]. A
study in 2006 looked at the specific findings in the EOM in patients
with CPEO using high-resolution orbital MRI. Unusual signal abnorm-
alities were noted in the EOM with diminished function, particularly
in the superior rectus and levator muscles. In these muscles atrophy
was also seen, similar to that observed in neurogenic paralysis.
5.2.2. Kearns–Sayre Syndrome
5.2.2.1. Clinical features. Kearns–Sayre Syndrome (KSS) is a rare,
progressive mitochondrial disorder which presents with a character-
istic triad of: the development of retinitis pigmentosa, progressive
external ophthalmoplegia, and occurrence before the age of twenty.
Clinical examination in patients with KSS usually detects a ‘salt and
pepper’ retinopathy of the posterior fundus without the visual field
defects, optic disk pallor and attenuation of retinal vessels usually
seen in retinitis pigmentosa. Other neurological complications include
cerebellar ataxia, sub-clinical neuropathy, cognitive impairment and
deafness. KSS is a multi-system disorder and non-neurological
features include cardiomyopathy, complete heart block, short stature,
endocrinopathies and dysphagia. Interestingly stroke and epilepsy,
which are common in other mitochondrial encephalopathies, are
unusual in KSS. On CSF examination patients typically exhibit
increased protein and lactate with decreased folate levels.
5.2.2.2. MtDNA mutation. Kearns–Sayre Syndrome (KSS) is typically
caused by a large-scale, sporadic single mtDNA deletion, although
complex rearrangements can also lead to this disease. No specific
deletion is responsible for KSS as all large-scale single deletions will
involve multiple protein encoding and tRNA genes. The majority of
mtDNA deletions share similar characteristics, with most being
located in the major arc between the two proposed origins of
replication (OH and OL). MtDNA deletions are predominantly (~85%)
flanked by short direct repeats. About one third of these patients have
a 4977 bp deletion, known as the ‘common deletion’ which has a 13
base pair repeat sequence [76].
5.2.2.3. Neuropathological studies. The neurodegeneration observed
in KSS affects both white and grey matter in the brain (Fig. 4) with
widespread spongiform degeneration recognised as a key histological
feature of the disease. White matter changes are noted in the
cerebrum, cerebellum, thalamus, basal ganglia and spinal cord [51].
The appearance of the white matter depends upon the level of
mitochondrial dysfunction and varies from mild atrophy to extensive
vacuolation with a sieve-like appearance. Oligodendrocytes appear to
be more dependent on optimal mitochondrial activity as they are
preferentially affected in KSS. Examination of brain tissue under
electron microscope has demonstrated that splits in the intraperiod
line are responsible for the spongy appearance of myelin [77].
The grey matter changes and neuronal loss seen in KSS occur
predominantly in the cerebellum, the cerebrum and the brainstemwith
the cortex and the dentate nucleus being relatively spared. The
neuropathological findings described are in corroboration with various
neuroimaging studieswhich routinely showdiffuse cerebellar, cerebrum
Fig. 4. Single large-scale mtDNA deletion: Significant Purkinje cell loss and severe
demyelination seen in cerebellum in a patient with KSS (A, B).
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and brain stem atrophy. The relative absence of ATP-dependent ion
channels and water transporters in astrocytes of the grey matter is
thought to be the underlying pathogenic consequence of mitochondrial
dysfunction in these areas [78]. To delineate a mechanism for neuronal
loss the COX activity of neurones throughout the brain of a patient with
KSS were explored. Low levels of COX deficiency were found in the
cerebellum, hippocampus, motor cortex and spinal cordwith high levels
in the reticular formation, nucleus ambiguus and globus pallidus. This
inconsistency further highlights the role of a multifactorial neuronal
susceptibility to mitochondrial mutations.
Substantial cerebellar degeneration underlies the clinical finding of
cerebellar ataxia as the disease progresses. In the cerebellum there is
targeted loss of Purkinje cells with development of thicker dendritic
trees by the surviving cells apparently in an effort to fill the space. The
reason for the restricted depletion of Purkinje cells remains unclear,
especially as immunohistochemical analysis appears to suggest a
lower threshold for respiratory chain dysfunction within neurones of
the dentate nucleus. Other pathological changes include the deposi-
tion of calcium in the microvasculature of the globus pallidus and
thalamus with haemosiderosis also reported.
5.2.2.4. Mechanisms. A mouse model with a single large-scale
deletion, which exhibits many symptoms of KSS may provide us with
a better understanding of the pathogenesis of this disease in humans
[79]. Currently only skeletal and cardiac muscle have been investi-
gated however it may be possible to examine levels of mutation and
COX activity in different populations of neurones at different stages of
neurodegeneration. The major mechanistic studies in KSS brains have
focused on the changes seen in the choroid plexus. In situ hybridisa-
tion studies have suggested a possible explanation for the CSF findings
in KSS. High levels of deletion have been detected in choroid plexus
epithelial cells [78]. It is thought that themitochondrial dysfunction in
these cells leads to an impairment of the blood–brain barrier. This may
also play a key role in the pathogenesis of KSS whereby the active
transport of folates, which are essential in DNA and RNA synthesis and
serotonin metabolism as well as in synthesis of membrane phospho-
lipids, is impaired.
6. Potential therapeutic options
Treatment of mtDNA diseases, and in particular the neurological
features, remains a major challenge. A review of all therapies [80]
revealed little evidence for effective treatment in patients with
mtDNA disease. There have been few large clinical trials and
unfortunately those that have been performed have shown that
medication is either ineffective or toxic [81]. However, supportive
therapy is important in managing some of the complications; for
example anticonvulsants can control seizures, and diabetes and
deafness can be treated with insulin and hearing aids. Cardiac
involvement is also common in this group of patients and early
management to prevent cardiac failure or to treat cardiac conduction
defects is important.
Several groups have been exploring interventions which may
increase mitochondrial number or change the mitochondrial geno-
type. Endurance or resistance exercise is beneficial in patients with
improvedmuscle strength and quality of life [82,83], however, there is
no evidence that exercise improves the other neurological features.
Recent studies have shown that expression of peroxisome prolifera-
tors-activated receptor gamma (PPARgamma), coactivator alpha
(PGC1alpha) or administration of bezafibrate (PPARgamma panago-
nist) induced mitochondrial biogenesis and led to delayed onset of
myopathy [84]. Whilst bezafibrate has been used in the treatment of
patients withmitochondrial fatty acid defects [85], there have been no
published studies in patients with mtDNA disease.
There have been a number of experimental molecular approaches
based on either complementing the mtDNA defect or changing the
balance of mutated to wild-type mtDNA. To complement mtDNA
protein defects it is possible to express the wild-type protein
allotopically from nuclear transfected constructs. In cell lines carrying
the m.8993TNG NARPmutation, allotropic expression of the wild-type
ATPase 6 protein partially rescued the biochemical phenotype [86]. It
is also possible to complement mitochondrial tRNA defects. Yeast
cytosolic RNA can surprisingly be imported into human mitochondria
and it has been shown that the imported tRNALysCUU can partly rescue
the biochemical defect in cell lines carrying the m.8344ANG MERRF
mutation [87]. Techniques to shift the mitochondrial genotype have
also been investigated including the selective inhibition of mutated
mtDNA replication [88] and the import of restriction endonucleases
which specifically target the mutated mtDNA [89].
Another approach for the treatment of mitochondrial diseases is
expression of single subunit alternative oxidases (AOX) which are
found in many eukaryotes but not mammals. These oxidases have the
potential to bypass the biochemical defect in oxidative phosphoryla-
tion. Recent studies have shown that transgene AOX expression does
not produce a detrimental phenotype in Drosophilia and was able to
rescue the phenotype twodifferentmitochondrial diseasemodels [90].
Although there is considerable effort to develop treatment for
mtDNA diseases, most therapies are a long way from potential clinical
use. An alternative approach is to use the uniquematernal inheritance
pattern of mtDNA diseases to try to prevent the transmission of
mtDNA diseases from mother to offspring. Preimplantation genetic
testing is of value for some women with heteroplasmic mtDNA
defects. Pronuclear transfer in early stage embryos may over a novel
approach to preventing transmission of both heteroplasmic and
homoplasmic mtDNA disease [91].
7. Conclusion
This review has concentrated on describing the clinical and
neuropathological features of several different mtDNA diseases. This
group of diseases provides some unique challenges to the neuros-
cientists, not the least because of the very extensive and variable
clinical involvement. Understanding the pathogenesis of the neuro-
degenerative features is challenging because of the lack of good
animal models of mtDNA diseases. Whilst there have been animal
models of nuclear genes which subsequently affect mtDNA copy
number or replication, true inherited mtDNA defect models are
difficult to generate. It is difficult to manipulate the mitochondrial
genome in cells or animals, and unfortunately pathogenic mtDNA
mutations are poorly transmitted through the germ-line.
Very recent epidemiological studies have confirmed that mtDNA
disorders are much more common than previously thought, and
pathogenic mtDNA mutations are present in about 1 in 200 of the
population. This highlights the importance of further studies into the
clinical and pathological features of these diseases, particularly as we
believe understanding of the mechanisms involved in the neurode-
generation is essential if we are to develop effective treatments for the
future. Finally, studying mtDNA diseases may provide important
insights for both common neurodegenerative diseases and ageing in
which mtDNA defects are also found.
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